What volume of retatrutide solution should I inject based on my prescribed dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Retatrutide Injection Volume Calculation

The volume of retatrutide solution you should inject depends entirely on your prescribed dose and the concentration of your specific product formulation, which is not standardized in available evidence.

Critical Information Gap

The provided evidence does not contain FDA labeling or manufacturer specifications for retatrutide's commercial formulation, concentration, or reconstitution instructions 1. Without knowing whether your product is supplied as:

  • Pre-filled pen with fixed concentration
  • Multi-dose vial requiring reconstitution
  • Single-dose vial at specific mg/mL concentration

It is impossible to provide a specific mL volume recommendation.

Dosing Context from Clinical Trials

Established Dose Escalation Schedules

Clinical trials used the following weekly subcutaneous dosing regimens 2, 3:

  • Starting doses: 1 mg, 2 mg, or 4 mg depending on target maintenance dose
  • Maintenance doses: 4 mg, 8 mg, or 12 mg weekly
  • Escalation strategy: Lower starting doses (2 mg vs 4 mg) reduced gastrointestinal adverse events 2, 3

Typical Escalation Pattern

For the 12 mg maintenance dose group 2, 3:

  • Week 1-4: 2 mg weekly
  • Week 5-8: 4 mg weekly
  • Week 9-12: 8 mg weekly
  • Week 13+: 12 mg weekly

What You Must Do

Contact your prescribing physician or pharmacist immediately to obtain:

  1. The exact concentration of your retatrutide product (mg per mL)
  2. Your prescribed dose in milligrams
  3. Specific injection volume instructions for your formulation
  4. Proper injection technique for subcutaneous administration

Safety Considerations

  • Retatrutide caused dose-dependent increases in heart rate (up to 6.7 beats/min) that peaked at 24 weeks 4, 5
  • Gastrointestinal adverse events (nausea, diarrhea, vomiting) occurred in 35-50% of participants and were dose-related 2, 3
  • The medication demonstrated positive inotropic effects on human atrial tissue, suggesting direct cardiac effects 5

Never attempt to calculate injection volumes without verified product-specific information from your healthcare provider or pharmacist.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.